Concepedia

Author

Deborah Berg

Millennium Engineering and Integration (United States)

Also Known As

D T Berg, D. T. Berg, Deborah Berg, Deborah T. Berg

80

Publications

6.2K

Citations

29

H-Index

38

Concepts

All Affiliations

Millennium Engineering and Integration (United States)Dana-Farber Cancer InstituteTakeda (United States)Mayo Clinic in ArizonaEmory University
DB

About

Deborah Berg is an author at Millennium Engineering and Integration (United States) specializing in medicine, health sciences, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

1.3K

2

Health Sciences

9

9

1.2K

3

Immunology

6

6

431

4

Allergy

1

1

95

5

Allergy Medicine

1

1

95

Deborah Berg

×

43

Publications

6K

Citations

28

H-Index

YearCitations

Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia

Robert J. Mayer, Roger B. Davis, Charles A. Schiffer,

New England Journal of Medicine

1994

1.4K

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Philippe Moreau, Tamás Masszi, Norbert Grząśko,

New England Journal of Medicine

2016

1K

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Clara D. Bloomfield, David Lawrence, John C. Byrd,

PubMed

1998

696

Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia

Richard M. Stone, Deborah Berg, Stephen L. George,

New England Journal of Medicine

1995

451

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky,

The Lancet Oncology

2014

260

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

Richard M. Stone, Deborah Berg, Stephen L. George,

Blood

2001

213

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Paul G. Richardson, Rachid Baz, Michael Wang,

Blood

2014

200

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Shaji Kumar, William Bensinger, Todd M. Zimmerman,

Blood

2014

192

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti,

Blood

2017

122

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Hervé Avet‐Loiseau, Nizar J. Bahlis, Wee Joo Chng,

Blood

2017

111

Page 1